003220.KS KSC
Daewon Pharmaceutical Co., Ltd.
1W: +0.5%
1M: -1.0%
3M: -1.4%
YTD: -32.9%
1Y: -39.8%
3Y: -40.0%
5Y: -46.9%
₩7,890.00 ($5.88)
+0.00 (+0.00%)
Weekly Expected Move ±2.0%
₩7573
₩7732
₩7890
₩8048
₩8207
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$43.6B
+45.1% ▲
5Y CAGR: +11.8%
Capital Expenditures
$29.8B
+44.4% ▲
5Y CAGR: +13.6%
Free Cash Flow
$13.8B
+158.5% ▲
5Y CAGR: +8.5%
Dividends Paid
$6.4B
-1.1% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
$30.1B
+333.2% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $6.6B | $30.7B | $23.9B | $9.0B | $429M |
| Depreciation & Amort. | $17.8B | $19.4B | $17.6B | $19.8B | $23.7B |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$16.8B | -$34.1B | -$4.6B | -$27.0B | $25.6B |
| Other Non-Cash Items | $14.8B | $17.4B | $14.9B | $28.2B | -$6.2B |
| Operating Cash Flow | $22.4B | $33.3B | $51.7B | $30.0B | $43.6B |
| — Investing Activities — | |||||
| Capital Expenditures | -$11.7B | -$13.4B | -$21.9B | -$34.9B | -$42.1B |
| Acquisitions (Net) | -$14.6B | $161M | $0 | $21M | $15.9B |
| Investment Purchases | -$23.2B | -$17.8B | -$914M | -$15.9B | -$5.4B |
| Investment Sales | $6.9B | $1.7B | $2.8B | $3.5B | $18.5B |
| Other Investing | $949M | $1.6B | -$48.2B | $4.3B | $134M |
| Investing Cash Flow | -$41.6B | -$27.7B | -$68.3B | -$43.0B | -$13.0B |
| — Financing Activities — | |||||
| Net Debt Issuance | $36.4B | -$6.7B | $11.3B | $16.8B | -$265M |
| Stock Repurchased | -$86M | -$6.2B | $0 | $0 | $0 |
| Dividends Paid | -$3.1B | -$4.1B | -$7.3B | -$6.4B | -$6.4B |
| Other Financing | $15.1B | -$3.4B | $15.4B | -$10.7B | $13.3B |
| Financing Cash Flow | $48.5B | -$20.4B | $19.5B | -$298M | $6.6B |
| Net Change in Cash | $31.3B | -$14.7B | $3.0B | -$12.9B | $30.1B |
| Cash End of Period | $41.7B | $27.0B | $30.0B | $17.1B | $47.2B |
| Free Cash Flow | $10.7B | $20.0B | $31.1B | -$23.5B | $13.8B |